Intravitreal Bevacizumab for Diabetic Macular Edema

Conditions

• Diabetic Retinopathy
• Macular Edema

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• Bevacizumab — DRUG

Study Details

Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema. This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.

Key Dates

First listed

Jun 23, 2008

Status verified

Jun 2008

Related Studies

• National Eye Institute Biorepository for Retinal Diseases
  Recruiting · National Eye Institute (NEI) · Bethesda, Maryland
• Clinical Applications of Advanced Ophthalmic Imaging
  Recruiting · University of Miami · Miami, Florida
• Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
  Recruiting · University of Alabama at Birmingham · Birmingham, Alabama
• Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy
  Recruiting · University of Alabama at Birmingham · Birmingham, Alabama